D. Mark McClung serves as Sangamo’s Executive Vice President and Chief Operating Officer. He was appointed to the position in November 2021 to coordinate and oversee company operations. The core functions in his purview include European business operations, corporate and business development, alliance management, commercial, new product planning, patient advocacy, government relations, investor relations, corporate communications, facilities and information technology. He has been with Sangamo since May 2020, when he was hired as Executive Vice President and Chief Business Officer.

Prior to joining Sangamo, from 2015 through 2019, Mr. McClung was Vice President and General Manager of Global Oncology Commercial at Amgen, which he joined from Onyx Pharmaceuticals where he had served as Senior Vice President & Chief Commercial Officer. For two decades prior, Mr. McClung held roles of increasing responsibility at GlaxoSmithKline in marketing and sales, commercial operations, clinical development and product strategy, and general management in Canada, the United States, and Europe, including as Vice President and Head of Global Commercial for GSK Oncology from 2009 – 2013.

Mr. McClung completed graduate coursework at York University in Toronto and Wharton Business School at the University of Pennsylvania, and he received a bachelor’s degree in Human Kinetics and Biomedical Sciences from the University of Guelph in Ontario, Canada.